From the Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario K7L 3N6, Canada.
From the Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario K7L 3N6, Canada.
J Biol Chem. 2018 Nov 16;293(46):17716-17730. doi: 10.1074/jbc.RA118.004803. Epub 2018 Sep 25.
Calpains are intracellular, calcium-activated cysteine proteases. Calpain-3 is abundant in skeletal muscle, where its mutation-induced loss of function causes limb-girdle muscular dystrophy type 2A. Unlike the small subunit-containing calpain-1 and -2, the calpain-3 isoform homodimerizes through pairing of its C-terminal penta-EF-hand domain. It also has two unique insertion sequences (ISs) not found in the other calpains: IS1 within calpain-3's protease core and IS2 just prior to the penta-EF-hand domain. Production of either native or recombinant full-length calpain-3 to characterize the function of these ISs is challenging. Therefore, here we used recombinant rat calpain-2 as a stable surrogate and inserted IS1 into its equivalent position in the protease core. As it does in calpain-3, IS1 occupied the catalytic cleft and restricted the enzyme's access to substrate and inhibitors. Following activation by Ca, IS1 was rapidly cleaved by intramolecular autolysis, permitting the enzyme to freely accept substrate and inhibitors. The surrogate remained functional until extensive intermolecular autoproteolysis inactivated the enzyme, as is typical of calpain-2. Although the small-molecule inhibitors E-64 and leupeptin limited intermolecular autolysis of the surrogate, they did not block the initial intramolecular cleavage of IS1, establishing its role as a propeptide. Surprisingly, the large-molecule calpain inhibitor, calpastatin, completely blocked enzyme activity, even with IS1 intact. We suggest that calpastatin is large enough to oust IS1 from the catalytic cleft and take its place. We propose an explanation for why calpastatin can inhibit calpain-2 bearing the IS1 insertion but cannot inhibit WT calpain-3.
钙蛋白酶是细胞内的钙激活半胱氨酸蛋白酶。钙蛋白酶-3 在骨骼肌中含量丰富,其突变导致功能丧失会引起 2A 型肢带型肌营养不良症。与含有小亚基的钙蛋白酶-1 和 -2 不同,钙蛋白酶-3 同工型通过其 C 端五 EF 手结构域的配对形成同源二聚体。它还有两个在其他钙蛋白酶中找不到的独特插入序列(ISs):位于钙蛋白酶-3 蛋白酶核心内的 IS1 和五 EF 手结构域之前的 IS2。生产天然或重组全长钙蛋白酶-3 来表征这些 IS 的功能具有挑战性。因此,在这里我们使用重组大鼠钙蛋白酶-2 作为稳定的替代物,并将 IS1 插入其蛋白酶核心的等效位置。就像在钙蛋白酶-3 中一样,IS1 占据催化裂缝,限制了酶对底物和抑制剂的接近。在 Ca 激活后,IS1 被分子内自解迅速切割,使酶能够自由接受底物和抑制剂。该替代物保持功能,直到广泛的分子间自解导致酶失活,这是钙蛋白酶-2 的典型特征。尽管小分子抑制剂 E-64 和亮抑蛋白酶肽限制了替代物的分子间自解,但它们并没有阻止 IS1 的初始分子内切割,从而确立了它作为前肽的作用。令人惊讶的是,即使 IS1 完整,大分子量钙蛋白酶抑制剂钙蛋白酶抑制剂也完全阻断了酶的活性。我们认为钙蛋白酶抑制剂足够大,可以将 IS1 从催化裂缝中逐出并取代其位置。我们提出了一个解释,说明为什么钙蛋白酶抑制剂可以抑制带有 IS1 插入的钙蛋白酶-2,但不能抑制 WT 钙蛋白酶-3。